Lv41
580 积分 2024-09-16 加入
The expanding landscape of GLP-1 medicines
3个月前
已完结
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity
3个月前
已完结
RYK is a GPNMB receptor that drives MASH
3个月前
已完结
Amylin receptor subunit interactions are modulated by agonists and determine signaling
5个月前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
5个月前
已完结
Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
7个月前
已完结
Obesity drugs aren’t always forever. What happens when you quit?
7个月前
已完结
FRI-383 Comparative anti-fibrotic action of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
8个月前
已关闭
FRI-370 Hepatoprotective effects of efruxifermin treatment in GAN diet-induced obese and biopsy-confirmed mouse model of MASH
8个月前
已关闭
88-OR: Long-Acting Amylin Analog AZD6234 in Combination with the GLP-1R Agonist Semaglutide Enhances Body Weight and Fat Mass Loss in Diet-Induced Obese (DIO) Rats
9个月前
已关闭
皖公网安备34019202002308
